Company profile: Candel Therapeutics
1.1 - Company Overview
Company description
- Provider of viral cancer immunotherapies and a discovery platform. Offers CAN-2409, a genetically modified adenovirus to elicit individualized anti-tumor responses in prostate, pancreatic, and lung cancers; CAN-3110, a modified herpes simplex virus for recurrent high-grade glioma; enLIGHTEN Discovery Platform to create HSV-based viral immunotherapies for solid tumors; conducts clinical trials for prostate, brain, pancreatic, and lung cancers and provides an expanded access policy.
Products and services
- EnLIGHTEN Discovery Platform: A data-driven discovery platform leveraging human biology and advanced analytics to architect new HSV-based viral immunotherapies for solid tumors, enabling creation of candidates grounded in human biological insights
- CAN-2409: A genetically-engineered, adenoviral-based immunotherapy engineered to produce an individualized anti-tumor response in prostate, pancreatic, and lung cancers
- CAN-3110: A HSV-based immunotherapy using a genetically modified herpes simplex virus to treat recurrent high-grade glioma by enhancing anti-cancer immune responses in the brain
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Candel Therapeutics
TriLink BioTechnologies
HQ: United States
Website
- Description: Provider of custom oligonucleotides, modified nucleotides, long RNA and mRNA for the diagnostic, therapeutic and OEM markets, offering mRNA synthesis services and GMP mRNA manufacturing, CleanCap capping solutions, custom NTPs, specialty oligo synthesis, and in-house analytical method development and testing; also supplies CleanAmp PCR products and phosphoramidites.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TriLink BioTechnologies company profile →
OPKO Health
HQ: United States
Website
- Description: Provider of pharmaceuticals and diagnostics based on novel proprietary technologies, including NGENLA, a once-weekly human growth hormone analog for pediatric growth failure due to inadequate endogenous growth hormone secretion, and RAYALDEE, an extended-release oral calcifediol for treating secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OPKO Health company profile →
Stage Cell Therapeutics
HQ: Germany
Website
- Description: Provider of a proprietary Streptamer platform enabling rapid development and production of safe and efficient cell therapeutics; privately held biotech active since 2005.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stage Cell Therapeutics company profile →
Arrayit
HQ: United States
Website
- Description: Provider of proprietary life science technologies and consumables for disease prevention, treatment, and cure, including DNA microarrays for gene expression and genotyping, protein microarrays (antigens, antibodies, peptides), microarrayers (manufacturing robots), microarray software for controller, quantification, analysis, and design, microarray tools (pins, printheads, hybridization cassettes), and microarray scanners (colorimetric, CCD, sub-micron fluorescence).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arrayit company profile →
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Candel Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Candel Therapeutics
2.2 - Growth funds investing in similar companies to Candel Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Candel Therapeutics
4.2 - Public trading comparable groups for Candel Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →